Targeting sialylation to treat central nervous system diseases.

Lünemann, Jan D; von Gunten, Stephan; Neumann, Harald (2021). Targeting sialylation to treat central nervous system diseases. Trends in Pharmacological Sciences, 42(12), pp. 998-1008. Elsevier 10.1016/j.tips.2021.09.002

Text von_Gunten_Targeting_sialylation_to_treat.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (1MB)

Sialic acid-binding immunoglobulin-type lectins (SIGLECs) are membrane receptors that are preferentially expressed on immune cells and recognize sialylated proteins, lipids, and RNA. Sialic acids and signaling through SIGLECs are increasingly recognized for their essential roles in immune system homeostasis as well as nervous system development, plasticity, and repair. Dysregulated sialylation and SIGLEC dysfunctions contribute to several chronic diseases of the central nervous system (CNS) in which current therapeutic options are very limited. While only a few therapies targeting SIGLECs are currently being tested in clinical trials, the area emerged as one of the most dynamic and active fields in glycobiology and drug development. This review highlights recent insights into sialic acid and SIGLEC function in CNS pathologies and illustrates opportunities and challenges for the development of sialic acid-based and SIGLEC-targeted therapies for neurological diseases.

Interest & Impact

Downloads

3 since deposited on 19 Oct 2021
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item